Trial Profile

Effectiveness of DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the United States

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

09 Mar 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
09 Apr 2019 Planned primary completion date changed from 30 Sep 2018 to 30 Sep 2020.
09 Apr 2019 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com